ImExHS Limited Reports FY25 Results
ImExHS Limited announced its financial results for the year ended 31 December 2025 on 27 February 2026. The company, listed on the ASX All Markets and operating in the health‑care software sector, achieved a top‑end performance relative to its guidance.
Revenue and Profitability
- FY25 revenue: $29.0 million, an increase of 10 % compared with the prior year and 6 % on a constant‑currency basis.
- FY25 recurring revenue: $28.5 million, up 11 % on a like‑for‑like basis when one‑off items are excluded.
- Underlying EBITDA: $1.6 million, a rise from $0.5 million in FY24 and at the upper end of the $1.3 million to $1.6 million guidance range.
The company reported no dividends during the period.
Operational Highlights
The FY25 results are supported by strong operational performance across both business segments:
| Metric | FY24 (Q4) | FY25 (Q4) |
|---|---|---|
| Installed sites | 8.3 million | 8.6 million |
| Studies reported | 3.6 million | 3.9 million |
| Portal users | 2.3 million | 2.6 million |
| Active patients with digital access | 8.2 million | 8.5 million |
| Portal sessions | 2.3 million | 2.6 million |
| Average sessions per user | 2.3× | 2.5× |
| Net Promoter Score | 42.7 | 45.2 |
These figures demonstrate continued growth in user engagement and platform reliability over the eight quarters ending Q4 FY25.
Corporate Governance
On 27 February 2026, the board approved the Corporate Governance Statement for the year ended 31 December 2025. The statement confirms compliance with the Australian Securities Exchange Corporate Governance Principles and Recommendations, 4th Edition, and is available on the company’s investor‑relations website. The governance disclosures include the entity’s ABN (60 096 687 839) and the financial year end of 31 December 2025.
Summary
ImExHS Limited’s FY25 performance exceeded revenue guidance and achieved a positive EBITDA margin. Growth in recurring revenue, user engagement, and portal usage underpin the company’s position as a technology solution provider in the global healthcare imaging market.
